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http://dx.doi.org/10.1016/j.trsl.2016Overexpression of wingless-type MMTV integration site family 5A (WNT5A) plays a
significant role in melanoma cancer progression; however, the mechanism(s)
involved remains unknown. In breast cancer, the human antigen R (HuR) has been
implicated in the regulation of WNT5A expression. Here, we demonstrate that endog-
enous expression of WNT5A correlates with levels of active HuR in HTB63 and WM852
melanoma cells and that HuR binds to WNT5A messenger RNA in both cell lines.
Although theHuR inhibitorMS-444 significantly impairedmigration in bothmelanoma
cell lines, it reduced WNT5A expression only in HTB63 cells, as did small interfering
RNA knockdown of HuR. Consistent with this finding, MS-444-induced inhibition of
HTB63 cell migration was restored by the addition of recombinant WNT5A, whereas
MS-444-induced inhibition of WM852 cell migration was restored by the addition of
recombinant matrix metalloproteinase-9, another HuR-regulated protein. Clearly,
HuR positively regulates melanoma cell migration via at least 2 distinct mechanisms
making HuR an attractive therapeutic target for halting melanoma dissemination.
(Translational Research 2016;172:45–60)Abbreviations: AREs ¼ Adenylate uridylate rich elements; HOPP ¼ Heuristic online phenotype
prediction; MMP-9¼Matrix metalloproteinase-9; RBP¼ RNA binding protein; RIP¼ RNA binding
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.02.007now broadly accepted as playing a key role in promoting
melanoma cell invasion through complex receptor-
dependent mechanisms.2-4 In support of a functional
involvement of WNT5A in melanoma invasion, gene
expression profiling studies of melanoma tissues,
primary melanoma cell cultures, and established cell
lines have revealed that high WNT5A expression is
significantly associated with an invasive phenotype.5-7
Furthermore, in a cohort of patients with metastatic
melanomas, elevated WNT5A protein expression was
shown to correlate significantly with a poor outcome.8
Although a considerable amount of work has been pub-
lished on the function of the WNT5A protein in malig-
nant melanoma cells, several questions about WNT5A
biology remain to be addressed. One such fundamental
issue that has not been fully explored is related to the
mechanisms by which WNT5A expression is regulated.
To our knowledge, there are no reports on mutations
in the gene encoding for WNT5A in human45
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Background
Elevated wingless-type MMTV integration site
family 5A (WNT5A) expression has been posi-
tively associated with melanoma progression, but
it remains unclear how WNT5A expression is up-
regulated in melanoma. In the present study, we
investigated whether human antigen R (HuR) con-
trols WNT5A expression and thereby promotes
melanoma metastasis.
Translational Significance
The present study demonstrates that the co-
expression of HuR and WNT5A is characteristic
of the invasive melanoma cells HTB63 and
WM852 but not of the proliferative melanoma
cells MM170 and MM383. HuR-inhibition differ-
entially disrupts WNT5A expression in HTB63
and matrix metalloproteinase-9 in WM852 cells,
thereby impairing migration of both cell lines.
These findings make HuR an attractive anti-
invasive target for restricting metastasis of inva-
sive melanoma cells.
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sion in invasive melanomas is most likely due to altered
regulation(s) at the transcriptional and/or the transla-
tional level. Regarding the transcriptional regulation
of WNT5A expression, we have recently reported that
interleukin (IL)-6 stimulation increases WNT5A
expression in malignant melanoma in a p38a-MAPK–
dependent manner.9 Similar to IL-6, transforming
growth factor-beta has also been implicated in the tran-
scriptional regulation of WNT5A in melanoma10 as
well as other cancer types.11-13 In one of the few
detailed studies on the transcriptional regulation of
WNT5A, Ripka et al12 provided substantial support
for CUTL1 acting as a transcription factor that could
mediate transforming growth factor-beta–induced
WNT5A expression. In addition to the transcriptional
regulation, several other mechanisms can control pro-
tein expression including the post-transcriptional regu-
lation of messenger RNA (mRNAs) by RNA-binding
proteins (RBPs) and microRNAs, which in an orches-
trated way regulate transcript stability and translational
availability.14
Using cutting-edge photoactivatable ribonucleoside
enhanced crosslinking and immunoprecipitation tech-
nique, Lebedeva et al15 demonstrated human antigen R(HuR) binding sites in WNT5A mRNA in human cells.
HuR is a member of the embryonic lethal abnormal
vision (ELAV) family of RBPs that contains 3 RNA-
recognition motifs with the ability to bind adenylate-
and uridylate-rich elements (AREs) in a target
mRNA.16 These AREs are usually located in the
30UTR of target transcripts, and the binding of HuR often
results in mRNA stabilization and/or increased transla-
tion.17,18 In this context, it should be noted that
WNT5A mRNA has an extended 30UTR sequence that
contains several putative AREs towhichHuR can bind.19
The impact of HuR on a specific target mRNA is regu-
lated by both post-translational modifications of HuR it-
self and the presence of other RBPs and miRNAs.20-22
Among the many established HuR targets are the
transcripts of genes involved in cancer and
inflammation, including COX-2 and matrix
metalloproteinase-9 (MMP-9).23 Indeed, aberrant HuR
expression has been reported in malignancies such as
colon, breast, and prostate cancer,24-26 and altered
HuR expression/activity is believed to contribute to
tumor onset and progression.27 In contrast to other can-
cers, the role of HuR in malignant melanoma has not yet
been comprehensively studied. However, Serini et al28
did report that HuR stabilizes COX-2 mRNA and medi-
ates constitutive COX-2 expression in WM266-4 mela-
noma cells.
In the present study, we investigated if the RBP HuR
interacts with WNT5AmRNA to regulate WNT5A pro-
tein expression and the functional consequences of such
an interaction in melanoma cells.
METHODS
Cell culture. All melanoma cell lines were grown at
37C in a humidified atmospherewith 5%CO2. Initially,
WM852, MM170, and MM383 cells were kindly pro-
vided by Drs G€oran J€onsson and Jill Howlin of the
Department of Oncology, Lund University, Sweden
andwere later procured directly fromATCC&TheWis-
tar Institute. HTB63 cells were procured from ATCC.
HTB63 cells were maintained inMcCOY’s 5Amodified
medium, whereas MM170, MM383, and WM852 were
maintained in RPMI-1640 medium. The growth media
were supplemented with 10% fetal bovine serum
(FBS), 2-mM L-glutamine, 0.5-U/mL penicillin, and
0.5-U/mL streptomycin. All cell lines were regulatory
tested for the absence of mycoplasma infection.
HuR RNA-binding protein immunoprecipitation
analyses. The RNA-binding protein immuno-
precipitation (RIP) analysis was performed using the
Magna RIP kit (Millipore Corporation, Billerica,
Massachusetts) according to the manufacturer
instructions. Briefly, 2.0 3 106 HTB63 and WM852
cells were lysed in 250-mL RIP lysis buffer. After
Translational Research
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as RNA and protein input samples. A 100-mL aliquot of
the remaining supernatant was added to protein A/G
magnetic beads precoated with either 5 mg of HuR
antibody (sc-5261; Santa Cruz Biotechnology, Inc,
Dallas, Texas) or control immunoglobulin G (IgG)1
antibody (ab81216; Abcam, Cambridge, UK), and the
mixtures were subsequently incubated overnight at
4C. After immunoprecipitation (IP), the bead
suspensions were extensively washed, and 1/10th of
the suspension was removed to test the efficiency of
HuR-IP by Western blotting. The remaining bead
samples together with the input RNA sample were
then treated with proteinase K, and the RNA from
each sample was purified using the recommended
phenol:chloroform protocol, followed by RNA
precipitation overnight at 280C. The precipitated
RNA samples were washed, dissolved in 20-mL
RNase-free water used for complementary DNA
synthesis, and analyzed by qPCR for WNT5A, COX-
2, MMP-9, and GAPDH mRNA (primer sequences are
provided in the qPCR section). The relative amounts
of WNT5A, MMP-9, and COX-2 mRNA from the
HuR- and IgG-IPs were quantified by using the
comparative Ct method and normalized to the
amounts of nonspecific GAPDH mRNA in each
immunoprecipitate. The HuR RIP analysis was
repeated 3 times.
Transient small interfering RNA transfections. At
24 hours after seeding, cells were transfected with 50-
nM small interfering RNA (siRNA) prepared using
serum-free medium and Lipofectamine 2000
(Invitrogen Corporation, Carlsbad, California)
according to the manufacturer’s recommendations. At
6 hours after siRNA transfection, the medium was
changed to fresh growth medium; after 24 hours, it
was replaced with low-serum medium (with 1% FBS).
After 72 hours, the cells were harvested for RNA and/
or protein extraction. The siRNA sequences used to
target HuR were as follows: HuR si #1, target
sequence: 50-GCU CAG AGG UGA UCA AAG A-3’
(ON-TARGETplus siRNA, Thermo Scientific,
Rockford, Illinois); HuR si #2, target sequence: 50-
ACC AGT TTC AAT GGT CAT AAA-3’ (FlexiTube
siRNA, Qiagen GmbH, Hilden, Germany). ON-
TARGETplus Non-targeting siRNA #1 from Thermo
Scientific was used as a negative control.
Real-time quantitative reverse transcription polymerase
chain reaction. Total RNAwas purified with an RNeasy
kit (Qiagen GmbH) as described by the manufacturer.
Complementary DNA was synthesized and used as the
template in qPCR reactions with the Maxima SYBR
Green/ROX qPCR master mix (Thermo Scientific).
All qPCR reactions were performed using a StratageneMx3005P with the following settings: preheating for
10 minutes at 95C, 40 cycles of denaturation at
95C for 15 seconds, and annealing and extension at
either 60C for 60 seconds (for WNT5A, COX-2,
and housekeeping genes) or at 52C for 60 seconds
(for MMP-9). Relative quantification of the
expression levels was performed using the
comparative Ct method and normalized to the
expression of either GAPDH or to the geometric
mean of GAPDH, SDHA, and HPRT1. The primer
sequences used were as follows: WNT5A forward,
50-TCA GGA CCA CAT GCA GTA-3’; WNT5A
reverse, 50-CTC ATG GCG TTC ACC ACC-3’; COX-
2 forward, 50- CAG ACA ACA TAA ACT GCG CCT
TTT-3’; COX-2 reverse, 50- GAC TTC CTG CCC
CAC AGC AA-30; HuR forward, 50-TTG AAT CTG
CAA AAC TTA TTC GGG-3’; HuR reverse, 50- ACG
ACA CCT TAA TGG TTT TTG ACT-30; GAPDH
forward, 50-AAT TCC ATG GCA CCG TCA AGG
CTG-30; GAPDH reverse, 50-TCG CCC CAC TTG
ATT TTG GAG GGA-30; SDHA forward, 50-TGG
GAA CAA GAG GGC ATC TG-30; SDHA reverse, 50-
CCA CCA CTG CAT CAA ATT CAT G-30; HPRT1
forward, 50-TGA CAC TGG CAA AAC AAT GCA
GAC T-30 HPRT1 reverse, 50-CTT CGT GGG GTC
CTT TTC ACC AGC-30; MMP-9 forward
50-TTG ACA GCG ACA AGA AGT GG-30; MMP-9
reverse 50-GCC ATT CAC GTC GTC CTT AT-30.
Western blotting. For protein isolation, cells were dis-
solved in lysis buffer; 20-mM TRIS-HCl, 150-mM
NaCl, 30-mM sodium pyrophosphate, 50-mM NaF, 1-
mM EDTA (pH 8), 1.5-mM MgCl2, 0.2-mM sodium
orthovanadate, 10% glycerol, 1% Triton X-100, and 1
tablet of Roche Complete-Mini protease inhibitor
(from Roche Diagnostics, Indianapolis, Indiana),
vortexed and incubated on ice for 30 minutes. The
lysates were then centrifuged for 30 minutes at
14.000 rpm and 4C, and the supernatants were
collected and stored at 280C. Protein concentrations
were determined using Pierce BCA Protein Assay Kit
(Thermo Scientific). Protein samples were mixed with
Laemmli buffer supplemented with DTT (final
concentration 40 mM), boiled for 10 minutes, and
subjected to electrophoresis on 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis gels. The
separated proteins were subsequently transferred to
polyvinylidene fluoride membranes and incubated
with antibodies against WNT5A (R&D Systems,
Minneapolis, Minnesota), HuR (Santa Cruz
Biotechnology, Inc), or MMP-9 (Abcam). After
overnight incubation with the primary antibodies, the
membranes were washed and further incubated with
respective secondary antibodies (goat anti-mouse/or
rabbit or rabbit-anti goat HRP from Dako, Glostrup,
Fig 1. Cytoplasmic HuR accumulation is correlated with an increase in endogenous WNT5A expression. (A)
Whole-cell lysate (left panel) or the cytosolic fraction (right panel) of HTB63, MM170, MM383, and WM852
melanoma cells was analyzed for HuR protein expression by western blotting. To assess the purity of the cyto-
plasmic HuR extract, the membrane was re-probed with a-tubulin. Moreover, the membranes were stripped
and probed with anti-Lamin B and -Na,K-ATPase antibodies to detect possible cross-contamination. (B) The rela-
tive WNT5A mRNA expression level was determined in our panel of melanoma cell lines by qPCR (left panel).
The relative WNT5A mRNA expression level was normalized against the mRNA expression of the housekeeping
gene GAPDH. Endogenous WNT5A protein expression was analyzed in melanoma cell lines by western blotting
(right panel) using b-actin as a loading control. HuR, human antigen R; mRNA, messenger RNA; WNT5A,
wingless-type MMTV integration site family 5A.
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antigen-antibody complexes were visualized using
a chemiluminescent ECL reagent (Millipore
Corporation), and densitometric analysis was carried
out using Image Lab 3.0 software (Bio-Rad, Hercules,
California). An antibody against b-actin (Sigma
Aldrich, St. Louis, Missouri) was used to verify equal
protein loading.
The subcellular protein fractionation kit (Cat. No.
78840; Thermo Scientific) was used to separate cyto-
plasmic protein extracts frommelanoma cells according
to the manufacturer’s instructions. Protein concentra-
tions were determined, and the samples were prepared
for Western blotting as described previously. To deter-
mine the purity of the cytoplasmic HuR extract, the
membrane was re-probed with anti-a-tubulin
(1:30.000; from Abcam), -Lamin B (1:1000; from SantaCruz Biotechnology, Inc), and -Na,K-ATPase (1:5000;
from Abcam) antibodies.
WNT5A 30UTR luciferase reporter assay. HTB63 cells
were seeded in 12-well plates and transiently
transfected with negative control or HuR siRNA (HuR
si#1), as described previously. At 48 hours after
siRNA transfection, the cells were transfected with
25-ng empty luciferase reporter vector or 1 of 2
WNT5A 30UTR luciferase reporter vectors (vectors A
and B) prepared using serum-free medium and
Lipofectamine 2000 (Invitrogen Corporation)
according to the manufacturer’s recommendations.
The WNT5A 30UTR sequences corresponded to
nucleotides 1-2543 (vector A) and 2394-4376 (vector
B), with the numbers referring to nucleotides 30 of the
stop codon (accession no. NM.003392.3). All reporter
vectors were derived from the pEZX-MT01 vector
Fig 2. Interaction between the RNA-binding protein HuR andWNT5AmRNA.Whole-cell lysates from untreated
HTB63 and WM852 melanoma cells were immunoprecipitated with a specific HuR antibody, as described in
methods. The left panels (A and B) show specific pull-down of the HuR protein. Quantitative qPCRwas performed
to determine the relative fold expression of WNT5A and COX-2 enrichment in the HuR and IgG immunoprecip-
itates (A and B, right panels).We then normalized the relative amounts ofWNT5A and COX-2mRNA in the HuR-
and IgG-IPs by the amount of GAPDH mRNA in each IP. A representative blot and qPCR analyses of 3 indepen-
dent experiments are shown. HuR, human antigen R; IgG, immunoglobulin G; IP, immunoprecipitation; mRNA,
messenger RNA; WNT5A, wingless-type MMTV integration site family 5A.
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(purchased from GeneCopoeia, Rockville, Maryland).
At 24 hours after reporter vector transfection, the cells
were harvested and analyzed for firefly and Renilla
luciferase activities using Dual-Luciferase Reporter
Assay System (Promega, Madison, Wisconsin). For
each sample, the 30UTR-coupled firefly luciferase
activity was normalized against the control Renilla
luciferase activity.
MS-444 treatments. The compound MS-444 was
kindly provided by N.C. Meisner, Novartis Institutes
for Biomedical Research, Basel, Switzerland, diluted
in DMSO at a stock concentration of 10 mM and
stored at 220C. Cells were seeded in 12-well plates
and cultured for 24 hours in growth medium. The
growth medium was then replaced with serum-free
medium supplemented with MS-444 or an equivalentvolume of the solvent alone (DMSO). In the initial
dose-response experiments, HTB63 cells were
incubated for 3–24 hours with MS-444 concentrations
ranging from 2 to 50 mM. In subsequent experiments,
both HTB6 and WM852 cell lines were incubated for
6–12 hours with 30-mM MS-444 (the same amount of
DMSO was used in the control). After 6 hours of MS-
444 treatment, total RNA was extracted; total proteins
were isolated after 12 hours of MS-444 treatment. The
levels of mRNA and protein expression were analyzed
by qPCR and Western blotting.
Cell migration. Cell migration was evaluated in cell
culture inserts (BD Falcon, New York) with a pore
size of 8 mm. After 24 hours, the cells were washed
and pretreated with either DMSO or MS-444 for
6 hours. After incubation, the cells were detached
with Versene and resuspended in growth medium
Fig 3. Effect of HuR silencing on WNT5A protein expression in HTB63 and WM852 cells. HTB63 and WM852
cells were transfected with either negative control (NC) siRNA or HuR-targeting siRNAs (#1 and #2). After 72 h of
transfection, the efficiency of HuR knockdown and its effect onWNT5A protein levels were analyzed. Left panels
show western blots analyses of WNT5A and HuR in the human melanoma cell lines HTB63 (A) andWM852 (B).
b-Actin was used to ensure equal loading of all samples. A representative blot of 4 independent experiments is
shown. Right panels show densitometric analyses of WNT5A protein expression, with the data normalized to
b-actin. The results are presented as the means and SEM; *P , .05; **P , .01. HuR, human antigen R; SEM,
standard error of the mean; siRNA, small interfering RNA; WNT5A, wingless-type MMTV integration site
family 5A.
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using an automated cell counter (Countess; Invitrogen
Corporation), and 50,000 cells were suspended in 0.5-
mL cell medium (supplemented with 1% FBS) and
added to the upper chamber of cell culture inserts ineither the absence or presence of recombinant
WNT5A (rWNT5A; R&D Systems) and/or
recombinant MMP-9 (rMMP-9; Calbiochem, EMD
Chemicals, Gibbstown, USA). The lower chamber
was filled with 0.75 ml of medium containing 10%
Fig 4. Effect of MS-444 on WNT5A mRNA and protein expression in melanoma cell lines HTB63 and WM852.
At 24 h after seeding, the indicated melanoma cell lines were incubated with DMSO (control) or 30-mMMS-444
for 6 or 12 h. After treatment, total RNA and protein were harvested as described in methods. (A) qPCR analysis
for WNT5A mRNA expression in HTB63 and WM852 cells was performed after 6 h of treatment with MS-444.
The samples were normalized according to the expression of 3 housekeeping genes: GAPDH, SDHA, and HPRT1.
(B)Western blot analysis showingWNT5A protein expression in HTB63 andWM852 cells treated with either 30-
mMMS-444 or DMSO control for 12 h. b-Actin was used to ensure equal loading of all samples. Densitometric
analyses were performed, and the data were normalized against b-actin. Symbols denoting statistical significance
are as follows: ***P, .001. (C) HTB63melanoma cells were transfected with control or HuR siRNA and cultured
for 66 h. The siRNA-transfected cells were then treated with either DMSO or 30-mMMS-444 for the next 6 h.
The panel shows the response of each cell line to HuR silencing, MS-444 treatment, and the combination of HuR
siRNA and MS-444 relative to the control-treated cells at the mRNA level. The data represent the means and stan-
dard deviations from 4 independent experiments; the data were analyzed by 1-way ANOVA together with Bon-
ferroni’s multiple comparison tests. Symbols denoting statistical significance are as follows: *P , 0.05.
ANOVA, analysis of variance; HuR, human antigen R; mRNA, messenger RNA; ns, not significant; siRNA, small
interfering RNA; WNT5A, wingless-type MMTV integration site family 5A.
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Fig 5. The HuR inhibitor MS-444 reduces melanoma cell migration in both HTB63 andWM852melanoma cells.
The panels show transwell migration assay results for HTB63 (A) andWM852 (B) cells treated either with DMSO,
MS-444, or MS-444 in combination with rWNT5A. Migration assay was performed over 24 h and analyzed as
Translational Research
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Volume 172 Moradi et al 53FBS. The cells were allowed to migrate for 24 h at 37C
in a humidified atmosphere with 5% CO2. The rate of
migration was analyzed either by counting the cells or
as described by Prasad et al.29
Statistical analysis. All the experiments described
herein were repeated more than three times. Means
and standard deviations (SD; indicated as error bars
on all graphs) were calculated and plotted using Graph-
Pad Prism 5. Two-tailed, paired t-tests were used to
determine the significance of two experimental data.
All multiple group analyses were performed using
one-way ANOVA together with Bonferroni multiple
comparison test. The symbols denoting statistical
significance were as follows: *, P , .05; **, P , .01;
***, P , .001, ns; non significant.RESULTS
Increased cytoplasmic localization of HuR correlates
with WNT5A protein expression in melanoma
cells. Although the RBP HuR is predominantly nu-
clear,30 its function is linked to its cytoplasmic
accumulation.31 To investigate the possible role of
HuR in stabilizing and regulating WNT5A expression
in melanoma, we analyzed endogenous HuR protein
expression in a panel of melanoma cell lines (HTB63,
MM170, MM383 and WM852) by western blotting
(using total cell lysates). As shown in (Fig 1, A; left
panel), all of these melanoma cell lines expressed
HuR; however, cell fraction analysis revealed high
cytoplasmic (active) HuR levels in HTB63 and
WM852 melanoma cells in comparison with MM170
and MM383 cells (right panel). To examine whether
HuR expression levels correlate with WNT5A
expression in melanoma cells, we carried out
quantitative reverse transcription polymerase chain
reaction and western blot analyses for WNT5A
mRNA and protein in our panel of melanoma cells.
qPCR analysis showed that all tested cell lines were
positive for WNT5A mRNA expression (Fig 1, B; left
panel), though only HTB63 and WM852 cells
exhibited WNT5A protein expression. These findings
correlate with the relatively high cytoplasmic HuR
(active) expression observed (Fig 1, B; right panel)described in methods. The data represent the means and sta
ANOVA together with Bonferroni’s multiple comparison test
expression in HTB63 and WM852 cells treated with 30-mM
loading. (D) A specific HuR antibody and a control IgG ant
untreated HTB63 and WM852 melanoma cells, as describe
down of the HuR protein. qPCR analyses were performed to
in the HuR and IgG immunoprecipitates. Representative blo
are shown. Symbols denoting statistical significance are as
ANOVA, analysis of variance; HuR, human antigen R; I
mRNA, messenger RNA; MMP-9, matrix metalloproteinaseand demonstrate that the cytoplasmic expression of
the RBP HuR (active) might be important for the post-
transcriptional regulation of WNT5A expression in
melanoma cells.
These findings are also in good agreement with the
phenotypical stratification by HOPP algorithm7 of
HTB63 and WM852 melanoma cells (Supplementary
data Fig S1), as it characterizes them as invasive, in
contrast toMM170 andMM383 cells, which are charac-
terized as proliferative (Supplementary data Fig S1).
The RBP HuR physically interacts with WNT5AmRNA. For
HuR to directly regulateWNT5A post-transcriptionally,
HuR needs to interact physically with WNT5A
transcripts. To test for this interaction, we subjected
whole-cell lysates from cell lines HTB63 and WM852
to RIP either in the presence of an antibody specific
for HuR or with a control IgG antibody. After RIP,
total RNA was isolated from the HuR/IgG IPs and
subsequently analyzed by qPCR using a WNT5A-
specific primer. COX-2 mRNA, which is known to
bind HuR protein, was used as a positive control.28 To
compensate for the nonspecific pull-down of RNA, we
normalized the relative amounts of WNT5A and
COX-2 mRNA in the HuR- and IgG-IPs according to
the amount of GAPDH mRNA in each IP. Fig 2, A
and B (left panel) demonstrate successful pull-downs
of HuR from lysates of both HTB63 and
WM852 cells. Further analysis showed specific
enrichment of WNT5A mRNA in the HuR-IPs based
on both melanoma cells lines compared with the
control IgG-IPs (Fig 2, A and B; right panel). The
results in Fig 2 are derived from three separate
experiments; the results were similar, though the
levels varied among the experiments (Supplementary
data Fig S2). These data show that WNT5A mRNA is
indeed a binding partner for the RBP HuR. In the next
set of experiments, we investigated the functional
consequences of this HuR-WNT5A interaction.
HuR knockdown results in reduced WNT5A expression in
HTB63 cells but not in WM852 cells. To test whether the
HuR protein is involved in the post-transcriptional
regulation of WNT5A, we transiently transfected
melanoma cells (HTB63 and WM852) with twondard deviations; the data were analyzed by 1-way
s. (C)Western blot analysis showing MMP-9 protein
MS-444 for 12 h. b-Actin was used to ensure equal
ibody were used for RIP from whole-cell lysates of
d in methods. The upper panels show specific pull-
determine the relative presence of MMP-9 mRNA
ts and qPCR analyses of 3 independent experiments
follows: *P , 0.05; **P , 0.01; ****P , 0.0001.
gG, immunoglobulin G; IP, immunoprecipitation;
-9.
Fig 6. The inhibition of migration in WM852 cells is restored by human rMMP-9 but not in HTB63 cells. The
panels show transwell migration assay results of (A) WM852 and (B) HTB63 melanoma cells treated with either
DMSO or MS-444 for 6 h. After counting, the cells were added to the migration insert either in the absence or
presence of rMMP-9, and the migration assays were performed over 24 h and analyzed as described in methods.
The data represent the means and standard deviations; the data were analyzed by 1-way ANOVA together with
Bonferroni’s multiple comparison tests. (C) Human melanoma HTB63 cells were pretreated with either DMSO
or MS-444 for 6 h. After counting, the cells were added to the migration insert in the absence or presence of
rWNT5A alone or in combination with rMMP-9. The data represent the means and standard deviations; the
data were analyzed by 1-way ANOVA together with Bonferroni’s multiple comparison tests. Symbols denoting
statistical significance are as follows: *P, 0.05; **P, 0.01; ***P, 0.001; ****P, 0.0001. ANOVA, analysis
of variance; MMP-9, matrix metalloproteinase-9.
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(see Methods); western blot analysis was performed
using total cell lysates 72 h after HuR siRNA
transfection. HuR silencing resulted in a significant
decrease in WNT5A protein expression in
HTB63 cells (up to 40%; Fig 3, A) but had no sucheffect in WM852 cells (Fig 3, B), even when the
cells were transfected with a double dose (100 nM)
of HuR siRNA for 72 h or 96 h (data not shown).
Thereafter, we used only HuR siRNA #1 because the
results from the knockdown showed that this siRNA
produces more consistent and reproducible results
Translational Research
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were also confirmed at the mRNA level. Similar to
the effects on protein expression, HuR siRNA
knockdown resulted in a significant decrease in HuR
(ELAVL1) mRNA in both HTB63 and WM852 cells
(Supplementary data Fig S3, A), though decreased
WNT5A mRNA was observed only in HTB63 cells
(Supplementary data Fig S3, B). These results
suggest that HuR binds to and stabilizes WNT5A
mRNA, thereby regulating WNT5A protein
expression, in HTB63 cells. In contrast, no effect on
WNT5A protein expression was observed in
WM852 cells.
To further investigate how HuR binds to WNT5A
mRNA, we utilized two 30UTR luciferase reporter con-
structs containing overlapping parts of the WNT5A
30UTR cloned downstream of a luciferase reporter
gene (Supplementary data Fig S4, A; left panel). Con-
trol and HuR siRNA-transfected HTB63 cells were sub-
jected to a second transfection with either a control
reporter plasmid (pEZX-MT01 EV) or WNT5A
30UTR reporter plasmid (pEZX-MT01 A-30UTR or
pEZX-MT01 B-30UTR). Measurement of the relative
reporter activity revealed significantly lower luciferase
activity from the 30UTR reporter plasmids in the HuR-
silenced cells compared with the control siRNA-
transfected cells (Supplementary data Fig S4, A; right
panel). Importantly, HuR silencing did not significantly
affect the luciferase activity from the control plasmid
lacking a 30UTR sequence. Control experiments
demonstrated the successful knockdown of HuR
(ELAVL1) mRNA in the analyzed cells
(Supplementary data Fig S4, B). These results suggest
that the RBP HuR binds to the 30UTR of WNT5A
mRNA in melanoma cells.
The low-molecular-weight HuR inhibitor MS-444 reduces
WNT5A mRNA and protein expression. Initially in our
study we tried to analyze how HuR siRNA silencing
affected melanoma cell migration. However, initial
transfection experiment with siRNA for 72 h seriously
affected the basal migration of these cells, whereas
treatment with small molecular HuR inhibitor MS-444
for 6 h did not. This compound was described as
interfering with HuR function, thereby resulting in
decreased mRNA expression of HuR target genes,
e.g., IL-1b and IL-6.32 In time- and dose-response
experiments, we observed that MS-444 treatment of
HTB63 cells resulted in decreased WNT5A mRNA
levels, with maximal effects between 6-12 h and with
a dose ranging between 20 and 50 mM
(Supplementary data Fig S5, A and B). Based on
these results, we treated melanoma cells with 30 mM
MS-444 for 6 h and analyzed the effects on WNT5A
mRNA levels. As shown in Fig 4, A; MS-444treatment of HTB63 cells resulted in a significant
decrease in WNT5A mRNA, but had no effect on the
expression of HuR (Supplementary data Fig S6). In
addition, the effects of MS-444 on WNT5A protein
expression were analyzed after 12 h of treatment with
the HuR inhibitor. In HTB63 cells, we found
significant inhibition of WNT5A protein expression
after 12 h of MS-444 treatment (Fig 4, B). However,
similar to the HuR silencing experiments, MS-444
inhibition of HuR in WM852 cells did not result in
any change in either WNT5A mRNA or protein
expression (Fig 4, A and B). Because the siRNA-
mediated knockdown of HuR and the MS-444-
mediated inhibition of HuR operate at different levels,
we sought to investigate whether a combination of
both methods could result in a more potent reduction
in WNT5A mRNA and protein in HTB63 cells. The
data shown in Fig 4, C demonstrate that combined
treatment with HuR siRNA and MS-444 potentiated
the reduction in WNT5A mRNA expression.
However, this combined effect was not observed at the
protein level (data not shown). These complementary
data further support a direct role of HuR in the
regulation of WNT5A expression in HTB63 cells.
Inhibition of HuR reduces migration in both HTB63 and
WM852 melanoma cells. WNT5A expression has been
positively correlated with increases in melanoma cell
motility and invasion. In the current study, we demon-
strated that HuR can regulate WNT5A expression in
HTB63 melanoma cells. Thus, to investigate whether
the direct targeting of HuR (by MS-444) can impair
migration in HTB63 cells, we performed a transwell cell
migration experiment with HTB63 cells pretreated in
the absence or presence of MS-444 for 6 h. Treatment
with MS-444 resulted in a significant decrease in
HTB63 cell migration, which could be partially restored
by the addition of rWNT5A (Fig 5, A). Surprisingly,
identical MS-444 inhibition of HuR in WM852 cells
also resulted in the significant inhibition of their
migration. However, in accordance with our previous
results (Fig 4), this inhibition was not restored by
rWNT5A (Fig 5, B). Therefore, the ability of MS-444 to
inhibit WM852 cell migration suggests the involvement
of another HuR-dependent regulator of WM852
melanoma cell migration. Within this context, it is
interesting to note that the HuR protein has also been
shown to stabilize and control the translation of MMP-9,
a well-known regulator involved in tumor cell migration
and invasion.33 Accordingly, we next assessed the
presence of MMP-9 in HTB63 and WM852 cells in the
presence or absence of MS-444. Treatment with MS-
444 resulted in a marked decrease in MMP-9 protein in
WM852 cells, whereas no effect on MMP-9 was
observed in HTB63 cells (Fig 5, C).
Fig 7. A schematic overview of the signaling network explaining the dual mechanisms of HuR in melanoma cell
migration. The RNA-binding protein HuR interacts with WNT5A and MMP-9 mRNA (blue) in melanoma cells
(HTB63 and WM852), thus stabilizing the mRNAs resulting in increased protein levels. MS-444 inhibits the HuR
protein in melanoma cells (as indicated by the red lines). In WM852 cells with high endogenous WNT5A expres-
sion, MS-444 inhibition of HuR did not cause any detectable changes in eitherWNT5AmRNA (orange) or protein
(yellow) levels. However, in these cells, MS-444 caused a significant reduction of MMP-9 (green) expression
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Volume 172 Moradi et al 57These results prompted us to further investigate
whether HuR binds physically to MMP-9 transcripts
in melanoma cell lines. We performed RIP with either
a HuR-specific antibody or a control IgG antibody. The
HuR protein was successfully pulled-down in both cell
lines (Fig 5, D; upper panel) and MMP-9 mRNA was
readily detectable in these HuR-IP, but not in the con-
trol IgG-IP (Fig 5, D; lower panel). Notably, the MMP-
9 mRNA fold enrichment in HTB63 cells was rela-
tively lower than that in WM852 cells. The results in
Fig 5, D are representative of 3 separate experiments.
All 3 experiments are shown in Supplementary data
Fig S7. Additionally, transfections with 2 independent
HuR-targeting siRNA oligos reduced HuR protein
levels in both cell lines (Supplementary data Fig S8,
A and B; left panels). In good agreement with our pre-
vious results (Fig 5, C), HuR silencing resulted in a sig-
nificant decrease in MMP-9 protein expression in
WM852 cells, although the effect was only statistically
significant for 1 of the 2 HuR siRNAs used
(Supplementary data Fig S8, B). However, no change
was detected in the MMP-9 protein level in HuR
siRNA-transfected HTB63 cells (Supplementary data
Fig S8, A).
In further experiments, we demonstrated that the inhi-
bition of WM852 cell migration by MS-444 (Fig 5, B)
depends on MMP-9, as the impairment of migration
by MS-444 was partially reversed by the addition of hu-
man rMMP-9 (Fig 6, A). In contrast and consistent with
the data presented in Fig 5, C, exogenous addition of hu-
man rMMP-9 did not restore HTB63 cell migration in
the presence of MS-444. (Fig 6, B). Furthermore, we
also demonstrate that addition of exogenous rMMP-9
did not further restore HTB63 cell migration in the pres-
ence of rWNT5A (Fig 6, C). Overall, these data show
that HuR can regulate melanoma cell migration by
affecting different regulatory proteins such as
WNT5A and MMP-9.DISCUSSION
WNT5A, a secreted glycoprotein and member of the
WNT family ligands, has been shown to act as either a
tumor suppressor or a tumor promoter.34 WNT5A has
been implicated as a tumor promoter in melanomas,leading to impaired melanoma cell migration restored by exo
limited binding of MMP-9 mRNA to HuR, MS-444 inhibiti
MMP-9 expression (orange and yellow). However, in thes
WNT5A mRNA and protein (green) expression leading to i
enous addition of rWNT5A. HuR, human antigen
metalloproteinase-9; rMMP-9, recombinant MMP-9; WNT
5A. (For interpretation of the references to color in this figu
of this article.)and its expression has also been positively associated
with melanoma progression and metastasis.4 However,
the regulatory mechanisms responsible for WNT5A up-
regulation in melanomas are still unclear. In breast can-
cer, where WNT5A has a tumor suppressor function,
HuR has been shown to negatively regulate WNT5A
protein expression by suppressing translation of its
mRNA.35 Important functions of the HuR protein
have also been implicated in other types of cancer, regu-
lating the expression levels of many tumor-promoting
factors (eg, Cox-2, VEGF and so forth) by stabilizing
their respective mRNAs.36 In the present study, we
explored the possibility that HuR protein can similarly
regulate WNT5A expression in malignant melanoma.
First, we investigated the HuR-WNT5A association by
analyzing HuR and WNT5A protein expression in 4
melanoma cell lines: HTB63, MM170, MM383, and
WM852. We demonstrated that of the 4 melanoma
cell lines tested, 2 (HTB63 and WM852 cells) display
high cytoplasmic (active) HuR expression as well as
WNT5A protein expression in comparison with the
other 2 cell lines (MM170 and MM383). Interestingly,
phenotypical stratification (by HOPP algorithm)
defined the HuR- and WNT5A-expressing HTB63 and
WM852 cells as having an invasive phenotype, whereas
the MM170 and MM383 cells were characterized as
proliferative. These findings suggest that HuR is
involved in positively regulating WNT5A protein
expression in HuR-expressing invasive melanoma cells,
perhaps by directly interacting with WNT5A mRNA.
We explored the mentioned possibility by performing
HuR RIP experiments, revealing a direct interaction be-
tween the HuR protein and WNT5A mRNA. Further-
more, in separate experiments, we also defined the site
of HuR protein binding by demonstrating that the
30UTR region of WNT5A mRNA is responsible for
binding the HuR protein. The results clearly demon-
strate by different approaches that the HuR protein
binds to WNT5A mRNA in HTB63 and WM852 mela-
noma cells. These findings are consistent with the re-
sults of 2 previous studies in which HuR was found to
interact with WNT5A mRNA.15,35
We then assessed the functional consequences of this
HuR-WNT5A mRNA association via siRNA knock-
down of HuR in HTB63 and WM852 cells. HuRgenous addition of rMMP-9. In HTB63 cells with a
on of HuR did not cause any detectable changes in
e cells, MS-444 caused a significant reduction of
mpaired melanoma cell migration restored by exog-
R; mRNA, messenger RNA; MMP-9, matrix
5A, wingless-type MMTV integration site family
re legend, the reader is referred to the Web version
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tein level as well as the mRNA level in HTB63 cells.
Surprisingly, HuR knockdown in WM852 cells had no
effect on either the WNT5A mRNA or protein level,
despite the fact that the HuR protein was confirmed to
bind to WNT5A mRNA in this cell line. Similar find-
ings were observed after short-term treatment with the
low-molecular-weight HuR inhibitor MS-444 in both
HTB63 and WM852 cells. We speculate that the much
higher expression of WNT5A mRNA in WM852 mela-
noma cells is the reason why HuR inhibition in these
cells did not affect WNT5A mRNA or protein levels.
This suggests that WNT5A mRNA bound to HuR pro-
tein constitutes only a minor part of the total amount
of WNT5A mRNA in WM852 cells.
Several studies have demonstrated that high WNT5A
expression in melanoma is correlated with increased
cell migration and metastasis4,37 and that inhibition of
WNT5A signaling reduces the migration of melanoma
cells.38 In the present study, we also found relatively
high active HuR and WNT5A expression in invasive
melanoma cells compared with proliferative melanoma
cells. Interestingly, direct and indirect evidence support
a promigratory role for the HuR protein in various can-
cers.39-42 Consequently, we tested whether HuR
inhibition could hinder the migration of melanoma
cell lines. To our surprise, despite the fact that treating
WM852 cells with MS-444 had no effect on WNT5A
levels, we did observe that MS-444 treatment led to a
significant decrease in migration of both HTB63 and
WM852 melanoma cells. Furthermore, the addition of
rWNT5A significantly restored migration in MS-444–
treated HTB63 cells, but not in WM852 cells. As HuR
can stabilize and regulate different target mRNAs, we
hypothesized that HuR regulates another promigratory
factor in WM852 melanoma cells, which could explain
the decreased migration of these cells on MS-444 treat-
ment. MMP-9 mRNA has been documented as being
regulated by HuR and also as promoting the migration
and metastasis of different types of cancer, including
melanoma, breast, and colon.42-44 To evaluate whether
the MS-444-induced inhibition of WM852 cell migra-
tion was mediated by MMP-9 downregulation, we
analyzed MMP-9 protein expression in both HTB63
and WM852 melanoma cells after treatment with MS-
444. We observed reduction in MMP-9 protein expres-
sion only in WM852 cells, but not in HTB63 cells.
Similar results for MMP-9 expression in WM852 cells
were obtained in our validation experiments using a
HuR siRNA approach. Our RNA immunoprecipitation
data revealed a direct interaction between the RBP
HuR and MMP-9 mRNA in both HTB63 and WM852
melanoma cells. However, we observed a higher enrich-
ment of MMP-9 mRNA in the HuR pull-down fromWM852 cells compared with the HuR pull-down from
HTB63 cells. This is a reasonable explanation for our
observation that HuR inhibition had no effect on the
MMP-9 expression in HTB63 cells. Our data are in
good agreement with those published by Akool
et al,45 who demonstrated that HuR binds to AREmotifs
of the 30UTR of MMP-9 mRNA.
In further support of this finding, our reconstitution ex-
periments revealed that active rMMP-9 restored impaired
migration in MS-444-treated WM852 cells. These find-
ings are in good agreement with those presented by
Yuan et al,46 who demonstrated that HuR silencing re-
sulted in the reduction of breast cancer cell growth and
invasion via the downregulation of MMP-9, and a study
performed on hepatocellular carcinoma showing that in-
hibition of cytosolic HuR by N-benzylcantharidinamide
suppresses cell invasion by inhibiting MMP-9 expres-
sion.33 Furthermore, RNAi-mediated MMP-9 silencing
resulted in the inhibition of migration and invasion in
mouse melanoma cells both in vitro and in vivo.43 Our
current view of howHuR regulatesmelanoma cell migra-
tion has been schematically outlined in Fig 7.
Melanoma comprises different cell types in which
different signaling pathways function cohesively to-
ward disease progression. Accordingly, the differences
in molecular profiles pose a large hurdle for therapeutic
treatment. Based on the present results, we believe that
targeting the HuR protein might be an effective strategy
to prevent melanoma progression, as HuR stabilizes
important promigratory molecules such as WNT5A
and MMP-9, which are well-known regulators of mela-
noma cell migration. Disruption of HuR-mRNA inter-
actions with small molecules such as MS-444 and
recently developed CMLD-247 constitutes valuable
tools for studying the role of HuR in cancer cell biology,
but it is possible that they might also be investigated as
potential drug candidates in the treatment of mela-
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